Regenxbio Inc.
Overview
Regenxbio Inc. is a biotechnology company focused on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company's NAV technology platform aims to provide innovative and life-changing solutions for patients with genetic diseases.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Regenxbio Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Related companies
Celerion, Inc.
United States
Charles River Laboratories International, Inc.
United States
Editas Medicine, Inc.
United States
Regeneron Pharmaceuticals, Inc.
United States
Altasciences Company Inc.
Canada
Boehringer Ingelheim BioXcellence GmbH
Germany
Heart Research Institute
Australia
Jamjoom Pharmaceuticals Factory Co.
Saudi Arabia
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.